The clinical research market in Poland has experienced remarkable growth, expanding from an estimated €200 million a decade ago to approximately €1.5 billion today. If current projections hold through 2030, the market could reach nearly €4.9 billion. This represents a staggering 25-fold increase over almost two decades, highlighting the rapid development of our industry.
Such exponential growth underscores why Poland has become a global hub for clinical trials. During an interview with Marek Klapa on Telewizja Biznesowa, Wojciech Kula discussed what makes the Polish market so attractive—from strong scientific infrastructure and skilled investigators to efficient regulatory processes and competitive costs.
This surge not only signifies a significant achievement for companies like Axcellant but also reflects Poland’s deeper integration into global clinical research networks. If the trajectory continues, the country is poised to play an even more influential role in developing the next generation of therapies.
Watch the full interview (in Polish) here.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant